CU20000126A7 - Tat del vih-1 derivados del mismo para vacunación profiláctica y terapéutica - Google Patents
Tat del vih-1 derivados del mismo para vacunación profiláctica y terapéuticaInfo
- Publication number
- CU20000126A7 CU20000126A7 CU20000126A CU20000126A CU20000126A7 CU 20000126 A7 CU20000126 A7 CU 20000126A7 CU 20000126 A CU20000126 A CU 20000126A CU 20000126 A CU20000126 A CU 20000126A CU 20000126 A7 CU20000126 A7 CU 20000126A7
- Authority
- CU
- Cuba
- Prior art keywords
- tat
- hiv
- nef
- gag
- rev
- Prior art date
Links
- 241000713772 Human immunodeficiency virus 1 Species 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title 1
- 238000002255 vaccination Methods 0.000 title 1
- 102000004127 Cytokines Human genes 0.000 abstract 3
- 108090000695 Cytokines Proteins 0.000 abstract 3
- 230000002519 immonomodulatory effect Effects 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 102000003812 Interleukin-15 Human genes 0.000 abstract 2
- 108090000172 Interleukin-15 Proteins 0.000 abstract 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 208000030507 AIDS Diseases 0.000 abstract 1
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 208000037357 HIV infectious disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108010067390 Viral Proteins Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000013612 plasmid Substances 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 229940021993 prophylactic vaccine Drugs 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 229940021747 therapeutic vaccine Drugs 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16041—Use of virus, viral particle or viral elements as a vector
- C12N2710/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente invención se refiere a Tat como el principioa ctivo para una vacuna profiláctica y/o terapéutica contra la infección del VIH, el progreso hacia el SIDA y el desarrollo de tumores y otros síndromes y síntomas en sujetos infectados por VIH. tat está en una forma biológicamente activa ya sea como protína o péptido recombinante o como ADN. de manera más particular, la invención se refiere a una vacuna basada en la tat del VIH-1 como inmunógeno, inoculado como ADN y/o proteína recombinante o como péptidos, sólos o en combinación con otors genes o productos génicos virales (nef, rev, gag) o partes de los mismos, en combinación con varias citocinas inmuno-modulantes (IL-12, IL-15) o con el gen que codifica para una citocina inmuno-modulante o parte de la misma. Tat, nef, rev, gag y las citocinas inmuno-modulantes se administran tanto como una mezcla de proteínas recombinantes, péptidos o proteínas de fusión (Tat/nef, tat/rev, tat/Gag, tat/IL-12, tat/IL15) o como el ADN de plásmido.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT97RM000743A IT1297090B1 (it) | 1997-12-01 | 1997-12-01 | Tat di hiv-1 o suoi derivati, da soli od in combinazione, a scopo vaccinale, profilattico e terapeutico, contro l'aids i tumori e le |
Publications (1)
Publication Number | Publication Date |
---|---|
CU20000126A7 true CU20000126A7 (es) | 2005-10-19 |
Family
ID=11405378
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU20000126A CU20000126A7 (es) | 1997-12-01 | 2000-05-31 | Tat del vih-1 derivados del mismo para vacunación profiláctica y terapéutica |
Country Status (23)
Country | Link |
---|---|
US (2) | US7744896B1 (es) |
EP (2) | EP1698347A3 (es) |
JP (1) | JP2001524531A (es) |
CN (1) | CN1283121A (es) |
AP (1) | AP2000001828A0 (es) |
AT (1) | ATE374041T1 (es) |
AU (1) | AU762893B2 (es) |
BR (1) | BR9814725A (es) |
CA (1) | CA2311647C (es) |
CU (1) | CU20000126A7 (es) |
CY (1) | CY1107818T1 (es) |
DE (1) | DE69838486T2 (es) |
DK (1) | DK1035865T3 (es) |
EA (1) | EA004330B1 (es) |
ES (1) | ES2293700T3 (es) |
IL (1) | IL136372A0 (es) |
IT (1) | IT1297090B1 (es) |
NZ (1) | NZ505373A (es) |
OA (1) | OA11419A (es) |
PL (1) | PL341818A1 (es) |
PT (1) | PT1035865E (es) |
TR (1) | TR200001553T2 (es) |
WO (1) | WO1999027958A2 (es) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1297090B1 (it) | 1997-12-01 | 1999-08-03 | Barbara Ensoli | Tat di hiv-1 o suoi derivati, da soli od in combinazione, a scopo vaccinale, profilattico e terapeutico, contro l'aids i tumori e le |
US20010008627A1 (en) | 1999-01-22 | 2001-07-19 | Soll David R. | Hiv-encoded chemoattractant |
CA2367692A1 (en) * | 1999-03-15 | 2000-09-21 | Introgen Therapeutics, Inc. | Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses |
WO2000078969A1 (en) * | 1999-06-21 | 2000-12-28 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hiv tat peptides and multiple peptide conjugate system |
KR100379577B1 (ko) * | 2000-07-26 | 2003-04-08 | 최수영 | 세포침투성 티에이티 - 인간 글루탐산 탈수소효소 융합단백질, 이 융합단백질을 코딩하는 재조합폴리뉴클레오타이드, 이 융합단백질의 발현벡터 및 이융합단백질을 세포 내로 도입하는 방법 |
NO314587B1 (no) * | 2000-09-04 | 2003-04-14 | Bionor Immuno As | HIV regulatoriske- og hjelpepeptider, antigener, vaksinepreparater, immunoassay testsett og en metode for påvisning av antistoffer fremkaltav HIV |
EP1279404A1 (en) * | 2001-07-26 | 2003-01-29 | Istituto Superiore di Sanità | Use of HIV-1 tat, fragments or derivatives thereof, to target or to activate antigen-presenting cells, to deliver cargo molecules for vaccination or to treat other diseases |
WO2003020876A2 (en) * | 2001-08-31 | 2003-03-13 | Chiron Corporation | Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof |
WO2003054006A2 (en) * | 2001-12-11 | 2003-07-03 | Aventis Pasteur | Mutated hiv tat |
FR2834717B1 (fr) * | 2002-01-11 | 2004-12-10 | Bio Merieux | Mutants de la proteine tat du virus vih-1 |
WO2003097675A1 (en) | 2002-05-16 | 2003-11-27 | Bavarian Nordic A/S | Fusion protein of hiv regulatory/accessory proteins |
AU2003268688A1 (en) * | 2002-09-30 | 2004-04-19 | Yamanouchi Pharmaceutical Co., Ltd. | Method of inducing immune responses |
CA2506695A1 (en) * | 2002-11-19 | 2004-06-03 | The Trustees Of The University Of Pennsylvania | Genetic constructs and compositions comprising rre and cte and uses thereof |
AU2003292136A1 (en) * | 2002-11-26 | 2004-06-18 | Eurocine Ab | Vaccines against viruses with cationic substances as adjuvants |
US8663622B2 (en) | 2002-12-16 | 2014-03-04 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Recombinant vaccine viruses expressing IL-15 and methods using the same |
GB0323840D0 (en) * | 2003-10-10 | 2003-11-12 | Ist Superiore Sanita | Vaccines |
US8062891B2 (en) | 2003-10-24 | 2011-11-22 | Gencia Corporation | Nonviral vectors for delivering polynucleotides to plants |
ES2411962T3 (es) | 2003-10-24 | 2013-07-09 | Gencia Corporation | Métodos y composiciones para suministrar polinucleótidos |
US20090123468A1 (en) | 2003-10-24 | 2009-05-14 | Gencia Corporation | Transducible polypeptides for modifying metabolism |
US8507277B2 (en) | 2003-10-24 | 2013-08-13 | Gencia Corporation | Nonviral vectors for delivering polynucleotides |
US8133733B2 (en) | 2003-10-24 | 2012-03-13 | Gencia Corporation | Nonviral vectors for delivering polynucleotides to target tissues |
GB2407501A (en) * | 2003-11-03 | 2005-05-04 | Ist Superiore Sanita | Nanoparticles for delivery of a pharmacologically active agent, comprising water insoluble (co)polymer core & hydrophilic acrylate-based (co)polymer shell |
US7927580B2 (en) | 2004-03-16 | 2011-04-19 | Nanirx, Inc. | Tat-based immunomodulatory compositions and methods of their discovery and use |
FR2868318B1 (fr) * | 2004-04-01 | 2012-11-16 | Commissariat Energie Atomique | Antigene tat stabilise et ses applications pour la vaccination anti-vih |
TW200613554A (en) * | 2004-06-17 | 2006-05-01 | Wyeth Corp | Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV |
US8668905B2 (en) | 2005-05-12 | 2014-03-11 | University Of South Florida | P53 vaccines for the treatment of cancers |
JP2010500407A (ja) | 2006-08-14 | 2010-01-07 | サイモン・エル・エル・シー | Hiv−1の複数の株及びサブタイプを治療及び予防するための組成物及び方法 |
GB0802224D0 (en) * | 2008-02-06 | 2008-03-12 | Inst Superiore Di Sanito | Process for the production of vaccine components |
US9439922B2 (en) * | 2008-05-14 | 2016-09-13 | Jawaharlal Nehru Centre For Advanced Scientific Research | Tat DNA sequences, gene constructs, vaccine and processes thereof |
NZ595060A (en) | 2009-03-23 | 2013-05-31 | Pin Pharma Inc | Treatment of cancer with immunostimulatory hiv tat derivative polypeptides |
CN102153657A (zh) * | 2011-01-18 | 2011-08-17 | 陕西师范大学 | IL-24-Tat PTD融合蛋白及其构建方法和应用 |
GB201301119D0 (en) * | 2013-01-22 | 2013-03-06 | Vaxxit Srl | Viral vaccines |
EP2969006A4 (en) * | 2013-03-14 | 2016-11-02 | David Gladstone Inst | COMPOSITIONS AND METHODS FOR TREATING INFECTION WITH IMMUNODEFICIENCY VIRUSES |
EP3052127A1 (en) | 2013-10-04 | 2016-08-10 | PIN Pharma, Inc. | Immunostimulatory hiv tat derivative polypeptides for use in cancer treatment |
CN103936863B (zh) * | 2014-04-23 | 2017-01-04 | 西安交通大学 | 一种调控stat3磷酸化的融合肽及其应用 |
CN104001155B (zh) * | 2014-06-12 | 2016-04-13 | 中山大学 | 一种Tat蛋白及其制备方法和应用 |
EP2982693A1 (en) * | 2014-08-07 | 2016-02-10 | Affimed Therapeutics AG | CD3 binding domain |
WO2018217897A1 (en) * | 2017-05-23 | 2018-11-29 | David Weiner | Compositions and method for inducing an immune response |
CN109943590B (zh) * | 2019-04-18 | 2022-11-18 | 西南大学 | 一种复制缺陷型猪圆环病毒、其制备方法及应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT83682B (en) * | 1985-11-06 | 1988-12-05 | Smithkline Beckman Corp | Process for the expression of an aids virus gene |
US5747641A (en) * | 1989-12-21 | 1998-05-05 | Biogen Inc | Tat-derived transport polypeptide conjugates |
US5646120A (en) * | 1990-10-24 | 1997-07-08 | Allelix Biopharmaceuticals, Inc. | Peptide-based inhibitors of HIV replication |
EP0491218A1 (en) * | 1990-12-17 | 1992-06-24 | F. Hoffmann-La Roche Ag | Benzodiazepinones |
US6107062A (en) * | 1992-07-30 | 2000-08-22 | Inpax, Inc. | Antisense viruses and antisense-ribozyme viruses |
WO1994015634A1 (en) * | 1992-12-30 | 1994-07-21 | Matthias Rath | Tat and rev oligopeptides in hiv treatment |
WO1995031999A1 (en) * | 1994-05-23 | 1995-11-30 | Immunogiology Research Institute, Inc. | Compositions of transactivating proteins of human immunodeficiency virus |
US6024965A (en) | 1996-10-18 | 2000-02-15 | Erasums University Rotterdam | Induction of REV and TAT specific cytotoxic T-cells for prevention and treatment of human immunodeficiency virus (HIV) infection |
IT1297090B1 (it) | 1997-12-01 | 1999-08-03 | Barbara Ensoli | Tat di hiv-1 o suoi derivati, da soli od in combinazione, a scopo vaccinale, profilattico e terapeutico, contro l'aids i tumori e le |
JP2003529559A (ja) * | 2000-01-31 | 2003-10-07 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 新規用途 |
-
1997
- 1997-12-01 IT IT97RM000743A patent/IT1297090B1/it active IP Right Grant
-
1998
- 1998-11-30 PL PL98341818A patent/PL341818A1/xx unknown
- 1998-11-30 US US09/555,534 patent/US7744896B1/en not_active Expired - Fee Related
- 1998-11-30 WO PCT/EP1998/007721 patent/WO1999027958A2/en active IP Right Grant
- 1998-11-30 JP JP2000522943A patent/JP2001524531A/ja active Pending
- 1998-11-30 EP EP05026908A patent/EP1698347A3/en not_active Withdrawn
- 1998-11-30 IL IL13637298A patent/IL136372A0/xx not_active IP Right Cessation
- 1998-11-30 PT PT98966601T patent/PT1035865E/pt unknown
- 1998-11-30 EA EA200000596A patent/EA004330B1/ru not_active IP Right Cessation
- 1998-11-30 DE DE69838486T patent/DE69838486T2/de not_active Expired - Lifetime
- 1998-11-30 ES ES98966601T patent/ES2293700T3/es not_active Expired - Lifetime
- 1998-11-30 AT AT98966601T patent/ATE374041T1/de active
- 1998-11-30 TR TR2000/01553T patent/TR200001553T2/xx unknown
- 1998-11-30 AP APAP/P/2000/001828A patent/AP2000001828A0/en unknown
- 1998-11-30 BR BR9814725-0A patent/BR9814725A/pt not_active IP Right Cessation
- 1998-11-30 AU AU24126/99A patent/AU762893B2/en not_active Ceased
- 1998-11-30 EP EP98966601A patent/EP1035865B1/en not_active Expired - Lifetime
- 1998-11-30 NZ NZ505373A patent/NZ505373A/en not_active IP Right Cessation
- 1998-11-30 DK DK98966601T patent/DK1035865T3/da active
- 1998-11-30 CN CN98812496A patent/CN1283121A/zh active Pending
- 1998-11-30 CA CA2311647A patent/CA2311647C/en not_active Expired - Fee Related
-
2000
- 2000-05-30 OA OA1200000159A patent/OA11419A/en unknown
- 2000-05-31 CU CU20000126A patent/CU20000126A7/es unknown
-
2007
- 2007-11-29 CY CY20071101530T patent/CY1107818T1/el unknown
-
2009
- 2009-05-06 US US12/436,119 patent/US8197820B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
DE69838486T2 (de) | 2008-06-26 |
WO1999027958A3 (en) | 1999-07-22 |
CY1107818T1 (el) | 2013-06-19 |
EP1698347A3 (en) | 2006-12-20 |
NZ505373A (en) | 2003-07-25 |
CA2311647C (en) | 2013-03-19 |
ITRM970743A1 (it) | 1999-06-01 |
US20100015087A1 (en) | 2010-01-21 |
ATE374041T1 (de) | 2007-10-15 |
JP2001524531A (ja) | 2001-12-04 |
WO1999027958A2 (en) | 1999-06-10 |
EP1035865A2 (en) | 2000-09-20 |
IT1297090B1 (it) | 1999-08-03 |
PT1035865E (pt) | 2007-12-07 |
IL136372A0 (en) | 2001-06-14 |
PL341818A1 (en) | 2001-05-07 |
AU762893B2 (en) | 2003-07-10 |
CA2311647A1 (en) | 1999-06-10 |
TR200001553T2 (tr) | 2000-11-21 |
CN1283121A (zh) | 2001-02-07 |
DE69838486D1 (de) | 2007-11-08 |
EA200000596A1 (ru) | 2000-12-25 |
US8197820B2 (en) | 2012-06-12 |
EP1698347A2 (en) | 2006-09-06 |
DK1035865T3 (da) | 2008-02-04 |
WO1999027958A9 (en) | 1999-09-10 |
EA004330B1 (ru) | 2004-04-29 |
AU2412699A (en) | 1999-06-16 |
AP2000001828A0 (en) | 2000-06-30 |
ES2293700T3 (es) | 2008-03-16 |
EP1035865B1 (en) | 2007-09-26 |
OA11419A (en) | 2004-04-21 |
BR9814725A (pt) | 2000-10-03 |
US7744896B1 (en) | 2010-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CU20000126A7 (es) | Tat del vih-1 derivados del mismo para vacunación profiláctica y terapéutica | |
Seiki et al. | Expression of the pX gene of HTLV-I: general splicing mechanism in the HTLV family | |
Kan et al. | Identification of HTLV-III/LAV sor gene product and detection of antibodies in human sera | |
ES2307496T3 (es) | Composiciones de vacuna, antigenos y peptidos. | |
ES2267199T3 (es) | Nuevos inmunogenos anti-vih (toxoides), procedimientos de preparacion y aplicacion para la prevencion y para el tratamiento del sida. | |
ES2249648T3 (es) | Virus mva recombinante, y el uso del mismo. | |
ES2312465T3 (es) | Peptidos de vih de regiones conservadas en gag p17 y sus aplicaciones, tales como vacunas. | |
Brenner et al. | Heat shock protein–based therapeutic strategies against human immunodeficiency virus type 1 infection | |
CN110958887B (zh) | 编码hiv抗原的痘病毒载体及其使用方法 | |
ES2313166T3 (es) | Proteina de fusion de proteinas reguladoras/accesorias del vih. | |
DK1240186T3 (da) | Forbedringer i eller relateret til immunrespons mod HIV | |
Fast et al. | Human trials of experimental AIDS vaccines | |
JP2719917B2 (ja) | Aidsの原因ウィルスの糖蛋白質、該糖蛋白質の製造方法及びワクチン | |
FRANCHINI et al. | Highly attenuated HTLV type I env poxvirus vaccines induce protection against a cell-associated HTLV type I challenge in rabbits | |
Trivedi et al. | Intrarectal transmission of simian immunodeficiency virus in rhesus macaques: selective amplification and host responses to transient or persistent viremia | |
ES2296793T3 (es) | Peptidos de vih de regiones conservadas, tat, rev y wef y su aplicacion como por ejemplo componentes de vacuna. | |
RAUTMANN et al. | HIV-1 core proteins expressed from recombinant vaccinia viruses | |
Inada et al. | Phylogenetic analysis of feline immunodeficiency virus isolated from cats in Taiwan | |
US6080846A (en) | Composition containing a B epitope of the envelope glycoprotein of a retrovirus and a T epitope of another distinct protein of this retrovirus | |
US5688914A (en) | Composition containing a B epitope of the envelope glycoprotein of a retrovirus and a T epitope of another distinct protein of this retrovirus | |
EP2291392B1 (en) | Bifunctional molecules for inhibiting hiv entry | |
ES2399875T3 (es) | Composiciones de vacunas de ADN y procedimientos para su uso | |
JPH04506220A (ja) | ウイルス感染予防の誘導 | |
CA2325345A1 (en) | Medicaments for inducing cytotoxic t-cells | |
CN103451199A (zh) | 一种hiv-1多表位dna疫苗 |